Histogenics Corporation (NASDAQ:HSGX) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Monday.

A number of other equities research analysts also recently weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Histogenics Corporation in a research report on Thursday, May 11th. Zacks Investment Research raised Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Tuesday, May 16th. Finally, HC Wainwright set a $4.00 price objective on Histogenics Corporation and gave the company a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $5.25.

Shares of Histogenics Corporation (NASDAQ HSGX) remained flat at $1.84 during trading on Monday. The stock had a trading volume of 17,508 shares. The stock’s 50-day moving average is $1.84 and its 200 day moving average is $1.74. Histogenics Corporation has a 12 month low of $1.45 and a 12 month high of $4.47. The stock’s market cap is $40.79 million.

Histogenics Corporation (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. During the same period in the prior year, the company posted ($0.61) EPS. On average, equities research analysts expect that Histogenics Corporation will post ($1.09) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Histogenics Corporation (HSGX) Lowered to “Strong Sell” at ValuEngine” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/histogenics-corporation-hsgx-lowered-to-strong-sell-at-valuengine/1488191.html.

Large investors have recently modified their holdings of the company. Sabby Management LLC increased its stake in shares of Histogenics Corporation by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 150,531 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Histogenics Corporation by 51.1% in the fourth quarter. Renaissance Technologies LLC now owns 99,000 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 33,500 shares in the last quarter. Finally, Carl Domino Inc increased its stake in shares of Histogenics Corporation by 2.8% in the first quarter. Carl Domino Inc now owns 89,400 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,400 shares in the last quarter. 50.09% of the stock is owned by institutional investors and hedge funds.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.